Literature DB >> 12457253

Immunoglobulin failure and retreatment in Kawasaki disease.

K Durongpisitkul1, J Soongswang, D Laohaprasitiporn, A Nana, C Prachuabmoh, C Kangkagate.   

Abstract

Several cases of Kawasaki disease (KD) were unresponsive to the initial treatment with intravenous immunoglobulin (IVIG). We retrospectively analyzed all children admitted with KD to determine the occurrence and variables associated with the initial IVIG treatment failure. All patients who fulfilled the criteria for KD and were treated with a single dose (2 g/kg) of IVIG between January 1995 and August 2001 were enrolled. An analysis of the patients who had initially failed to respond to IVIG was performed. A total of 120 patients were enrolled during the study period. There were 68 boys (56.7%). Fourteen patients (11.6%) were found to be unresponsive to initial IVIG treatment. Patients who were anemic (Hb<10 G/DL), had a high neutrophil count (> 75%), a high band count, and low albumin were at risk of failure to respond to a single dose of IVIG. We found no correlation among age, gender, days since starting IVIG treatment, and erythrocyte sedimentation rate (ESR) with failure of the initial IVIG treatment. There were 12 patients (10%) who developed coronary artery aneurysms. The failure of a single dose of IVIG treatment occured in up to 11.6% of our Kawasaki patients. We found that low hemoglobin (<10 G/DL), high neutrophil count (> 75%), high band count, and a low albumin were associated with the requirement for retreatment with a second dose of IVIG.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12457253     DOI: 10.1007/s00246-002-0216-2

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  66 in total

1.  Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.

Authors:  M Miura; H Ohki; T Tsuchihashi; H Yamagishi; Y Katada; K Yamada; Y Yamashita; A Sugaya; O Komiyama; H Shiro
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

Review 2.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

Review 3.  Kawasaki Disease update.

Authors:  Jane C Burns
Journal:  Indian J Pediatr       Date:  2009-04-18       Impact factor: 1.967

4.  Infliximab treatment for pediatric refractory Kawasaki disease.

Authors:  Laura L Blaisdell; Jennifer A Hayman; Adrian M Moran
Journal:  Pediatr Cardiol       Date:  2011-07-20       Impact factor: 1.655

5.  A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.

Authors:  Meng Wei; Meirong Huang; Shubao Chen; Guoying Huang; Min Huang; Dingzhong Qiu; Zhongzhen Guo; Jingjing Jiang; Xiaoxun Zhou; Qing Yu; Ying Guo; Lijun Fu; Wei Gao; Feng Li
Journal:  Pediatr Cardiol       Date:  2015-03-27       Impact factor: 1.655

6.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.

Authors:  Tetsuya Sano; Shunji Kurotobi; Kouji Matsuzaki; Takehisa Yamamoto; Ichiro Maki; Kazunori Miki; Shigetoyo Kogaki; Junichi Hara
Journal:  Eur J Pediatr       Date:  2006-08-01       Impact factor: 3.183

7.  Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide.

Authors:  Kazunari Kaneko; Ken Yoshimura; Atsushi Ohashi; Takahisa Kimata; Tomohiko Shimo; Shoji Tsuji
Journal:  Pediatr Cardiol       Date:  2011-04-13       Impact factor: 1.655

8.  Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance.

Authors:  Miyu Tajima; Yusuke Shiozawa; Jiro Kagawa
Journal:  Pediatr Cardiol       Date:  2015-03-10       Impact factor: 1.655

9.  Kawasaki disease presenting as parotitis in a 3-month-old infant.

Authors:  Hyun-Jeong Do; Jong-Geun Baek; Hyun-Jung Kim; Jung-Sook Yeom; Ji-Sook Park; Eun-Sil Park; Ji-Hyun Seo; Jae-Young Lim; Chan-Hoo Park; Hyang-Ok Woo; Hee-Shang Youn
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

10.  Infliximab treatment for refractory kawasaki disease in korean children.

Authors:  Min Seob Song; Sang Bum Lee; Sejung Sohn; Jin Hee Oh; Kyung Lim Yoon; Ji Whan Han; Chul Ho Kim
Journal:  Korean Circ J       Date:  2010-07-26       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.